Form 4: Castle Biosciences CFO Sells Shares Under 10b5-1 Plan

Castle Biosciences' Chief Financial Officer, Frank Stokes, sold a total of 6,923 shares of common stock on November 15, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Frank Stokes, the Chief Financial Officer of Castle Biosciences, Inc., executed sales of company stock on November 15, 2024.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on August 13, 2024.
• A total of 6,123 shares were sold at a weighted average price of $29.87 per share.
• An additional 800 shares were sold at a weighted average price of $30.404 per share.
• The total number of shares sold was 6,923.
• Following these transactions, Mr. Stokes directly owns 30,823 shares of Castle Biosciences stock.

Sentiment

Score: 5

Explanation: The document reports a routine insider stock sale under a pre-arranged plan, which is neither particularly positive nor negative.

Risks

• Sales by company insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and these transactions are closely monitored by regulators and investors.

Comparison to Industry Standards

• Rule 10b5-1 plans are a common mechanism for corporate insiders to sell shares while avoiding accusations of trading on non-public information.
• The reported transactions are typical for executives who have pre-arranged trading plans.

Stakeholder Impact

• The stock sales may have a minor impact on shareholder sentiment, but are unlikely to have a significant effect on other stakeholders.

Key Dates

Keywords

insider trading, Form 4, stock sale, Rule 10b5-1, Castle Biosciences, CFO, Frank Stokes